Paper282922
Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).
Cunningham I and 9 others. Blood, 1979. Cited by 248 papers, by iCite.
Cite this record
ConductScience Library. Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Papers, record 282922. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/282922
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chromosomes, Human, 21-22 and Y | Major topic |
| Leukemia, Myeloid | Major topic |
| Adolescent | |
| Adult | |
| Asparaginase | |
| Cell Transformation, Neoplastic | |
| Cytarabine | |
| Female | |
| Humans | |
| Hydroxyurea | |
| Male | |
| Middle Aged | |
| Radiography | |
| Spleen | |
| Splenectomy | |
| Thioguanine |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 248 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 17882283 | The history of myeloproliferative disorders: before and after Dameshek. | Leukemia | 2008 | https://conductscience.org/library/papers/17882283 | PubMed |
| 17031690 | High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study. | Ann Hematol | 2007 | https://conductscience.org/library/papers/17031690 | PubMed |
| 12835715 | Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. | Leukemia | 2003 | https://conductscience.org/library/papers/12835715 | PubMed |
| 11551022 | Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. | Bone Marrow Transplant | 2001 | https://conductscience.org/library/papers/11551022 | PubMed |
| 9643527 | Treatment of chronic myelogenous leukaemia. | Med Oncol | 1998 | https://conductscience.org/library/papers/9643527 | PubMed |
| 7929813 | Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. | J Clin Invest | 1994 | https://conductscience.org/library/papers/7929813 | PubMed |
| 7003128 | Chemotherapy of the myeloid leukaemias. | J R Coll Physicians Lond | 1980 | https://conductscience.org/library/papers/7003128 | PubMed |
| 6938261 | Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation. | Blut | 1981 | https://conductscience.org/library/papers/6938261 | PubMed |
| 6751438 | Allogeneic marrow transplantation for chronic granulocytic leukemia. | Blut | 1982 | https://conductscience.org/library/papers/6751438 | PubMed |
| 6108135 | Haemopoietic stem cell autografts for leukaemia. | Blut | 1980 | https://conductscience.org/library/papers/6108135 | PubMed |
| 3459595 | Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3459595 | PubMed |
| 3277680 | Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. | Blut | 1988 | https://conductscience.org/library/papers/3277680 | PubMed |
| 3196882 | Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b. | Blut | 1988 | https://conductscience.org/library/papers/3196882 | PubMed |
| 3166389 | Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients. | Blut | 1988 | https://conductscience.org/library/papers/3166389 | PubMed |
| 3121203 | Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG). | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3121203 | PubMed |
| 2350591 | Restoration of nonclonal hematopoiesis in chronic myelogenous leukemia with interferon alpha. | Blut | 1990 | https://conductscience.org/library/papers/2350591 | PubMed |
| 2312599 | Chronic myelogenous leukemia: an overview. | J Cancer Res Clin Oncol | 1990 | https://conductscience.org/library/papers/2312599 | PubMed |
| 1803180 | Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation. | Med Oncol Tumor Pharmacother | 1991 | https://conductscience.org/library/papers/1803180 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/282922
GET https://conductscience.org/api/papers/v1/282922/authors